arrow_back Back to App

Extending Funding for Childhood Disease and Cancer Research

This law provides an additional $25 million annually from 2023 to 2027 for research into diseases affecting children, including cancer. The goal is to support new discoveries and therapies that can improve children's health and lives. The act emphasizes coordinating research to ensure funds are spent effectively.
Key points
Allocates $25 million per year from 2023 to 2027 for pediatric research.
Supports research into childhood cancer and other serious conditions.
Aims for better coordination of research to avoid duplicating efforts.
Requires a report on research progress and funding use within 5 years.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_623
Sponsor: Rep. Wexton, Jennifer [D-VA-10]
Process start date: 2021-01-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Gabriella Miller Kids First Research Act 2.0

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_623.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-28.

What are the main provisions?

Key points include:

  • Allocates $25 million per year from 2023 to 2027 for pediatric research.
  • Supports research into childhood cancer and other serious conditions.
  • Aims for better coordination of research to avoid duplicating efforts.
  • Requires a report on research progress and funding use within 5 years.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Wexton, Jennifer [D-VA-10].

What is the latest detailed status?

The latest detailed status is: The title of the measure was amended. Agreed to without objection.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health